biotech / news / / Scientific American
The vaccine must overcome the same obstacles that caused an earlier Lyme vaccine to be pulled from the market in 2002.
Pfizer and Valneva's Lyme vaccine showed 73–75% efficacy in phase 3 trials.
KEY POINTS
- Half the trial population was dropped due to quality concerns, reducing statistical power.
- LB6V targets six serotypes and lacks the LYMErix component linked to arthritic pain fears.
- Annual preseason booster shots will likely be required to maintain vaccine effectiveness.
- The vaccine was tested in children under 15, unlike the earlier LYMErix vaccine.
COMPANIES
Summarized by Newsio from Scientific American. How we summarize →